Related Experiment Video
Updated: May 29, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis C therapy: other players in the game
1Loyola University Medical Center, Maywood, IL 60153, USA.
Abstract:
Therapies in addition to the direct-acting antiviral agents (DAA) under evaluation for chronic hepatitis C include host targets such as cyclophilin inhibitors and immunomodulators. Both passive and therapeutic vaccines hold promise for the future. Although the numbers of drug categories and individual agents are increasing, only a handful of the non-DAAs seem to be ready to move on to phase III trials. New interferon agents are in development, and ribavirin variants are still under consideration. The role of the other players in the overall armamentarium against hepatitis C virus is still evolving.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Hepatic Drug Clearance: Role of Transporters

